CRNX Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

KUPNO 104529 min ago

@ $36.22

Wydano: 14 vas. 2024 @ 22:47

Zwrot: 16.29%

Poprzedni sygnał: vas. 14 - 19:28

Poprzedni sygnał: Sprzedaż

Zwrot: -0.41 %

Live Chart Being Loaded With Signals

Commentary (26 bal. 2024 @ 23:00):

Stats
Dzisiejszy wolumen	551 185
Średni wolumen	798 153
Kapitalizacja rynkowa	3.28B
EPS	$0 ( 2024-02-28 )
Następna data zysków	( $-0.840 ) 2024-05-02
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-11.41
ATR14	$0.0550 (0.13%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-18	Struthers Richard Scott	Sell	350	Common Stock
2024-04-15	Pizzuti Dana	Sell	14 375	Stock option (Right to Buy)
2024-04-15	Pizzuti Dana	Buy	14 375	Common Stock
2024-04-15	Pizzuti Dana	Sell	14 375	Common Stock
2024-04-15	Struthers Richard Scott	Buy	20 000	Common Stock

INSIDER POWER
20.03
Last 99 transactions
Buy: 1 532 159 \| Sell: 1 109 365

Wolumen Korelacja

Długi: -0.22 (neutral)

Krótki: 0.79 (moderate)

Signal:(66.221) Neutral

Crinetics Pharmaceuticals Korelacja

10 Najbardziej pozytywne korelacje
VYNE	0.883
CPIX	0.875
FULC	0.871
ARWR	0.869
RDUS	0.866
LITM	0.861
RNDM	0.858
SPRO	0.857
JAKK	0.844
ENTA	0.841

10 Najbardziej negatywne korelacje
ALGM	-0.894
SITM	-0.856
GMII	-0.853
PPBT	-0.85
GDRX	-0.835
UMPQ	-0.821
GFS	-0.815
SBBP	-0.801

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Crinetics Pharmaceuticals Korelacja - Waluta/Towar

0.71
( moderate )

0.56
( weak )

0.00
( neutral )

0.08
( neutral )

-0.04
( neutral )

-0.27
( neutral )

Crinetics Pharmaceuticals Finanse

Annual	2023
Przychody:	$4.01M
Zysk brutto:	$2.92M (72.64 %)
EPS:	$-3.69

FY	2023
Przychody:	$4.01M
Zysk brutto:	$2.92M (72.64 %)
EPS:	$-3.69

FY	2022
Przychody:	$4.74M
Zysk brutto:	$3.35M (70.68 %)
EPS:	$-3.08

FY	2021
Przychody:	$1 078.00
Zysk brutto:	$1 078.00 (100.00 %)
EPS:	$-0.00280

Financial Reports:

No articles found.

Crinetics Pharmaceuticals

Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly, as well as completed phase II clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). The company is also developing CRN04777, an oral selective nonpeptide somatostatin type 5 receptor agonist, which is in phase I clinical trial for the treatment of congenital hyperinsulinism; and CRN04894, an oral adrenocorticotrophic hormone antagonist that is in phase I clinical trial for the treatment of Cushing's and congenital adrenal hyperplasia diseases. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Aktualne aktualizacje dla Crinetics Pharmaceuticals [CRNX]

Upcoming Earnings Alert